Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
CytomX Therapeutics Inc. currently manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across an equal number of distinct examiners, meaning each individual is handling a unique portion of the pending portfolio. This distribution requires the company to navigate the specific preferences and styles of different individuals at the patent office, which can lead to varied prosecution outcomes across the 3 pending office actions.
All the actions are concentrated within 1 distinct art unit, indicating a specific technical focus for the current prosecution despite the variety of examiners. STOICA, ELLY GERALD is the busiest examiner with 1 pending office action. Because there are multiple examiners for the actions, each manages a matter. This arrangement in the distinct art unit ensures that while the examiners differ, the administrative and technical oversight remains within a single unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18400894 | MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF | STOICA, ELLY GERALD | — |
| 18354353 | ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF | CANELLA, KAREN A | — |
| 17230240 | MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18400894 | MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF | STOICA, ELLY GERALD | — | §112DP | Non-Final OA | — | Pending | Dec 29, 2023 |
| 18354353 | ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF | CANELLA, KAREN A | — | §112DP | Non-Final OA | — | Pending | Jul 18, 2023 |
| 17230240 | MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME | BRISTOL, LYNN ANNE | 1643 | Other | Non-Final OA | — | Pending | Apr 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial